Science

Shankar Siva: TFS at 1 year is approximately 90% with SABR

Shankar Siva/iconcancercentre.com.au

Feb 13, 2025, 17:28

Shankar Siva: TFS at 1 year is approximately 90% with SABR

Shankar Siva, Radiation Oncologist at Peter MacCallum Cancer Centre, shared a post on X by Daniel Heng, Head of Medical Oncology at the Arthur J.E. Child Comprehensive Cancer Centre in Calgary, adding:

“TFS (treatment breaks) at 1 year is approximately 90% with SABR; for selected patients, this might be the optimal choice!”

1. “Stereotactic Ablative Radiation for Systemic Therapy-naive Oligometastatic Kidney Cancer”

Authors: Raquibul Hannan et al.

2. “Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial”

Authors: Chad Tang et al.

Shankar Siva: TFS at 1 year is approximately 90% with SABR

3. “Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinoma-The RAPPORT Trial”

Authors: Shankar Siva et al.

Shankar Siva: TFS at 1 year is approximately 90% with SABR

Quoting Daniel Heng’s post, about a paper he co-authored with colleagues published in European Association of Urology:

“Treatment-free survival is becoming an important endpoint when looking at different mRCC treatments. VEGF alone had the shortest TFS. Something to be said about treatment breaks.”

“Treatment-free Survival After First-line Therapies for Metastatic Renal Cell Carcinoma: An International Metastatic Renal Cell Carcinoma Database Consortium Analysis”

Authors: Mehul Gupta, Connor Wells, Meredith Regan, Daniel Heng et al.

Daniel Heng: Treatment free survival is becoming an important endpoint in different mRCC treatments